jbog: i think they are dragging their feet. anal-ysts that ask questions are stupid. nobody asks tough questions that is material to shareholders. even if 3rd entrant comes to market, say they burn cash on 20m/year...you still don't need 350m of cash to get to 2014 copaxone launch - which they keep saying they are 100% positive. they only need another 60m. Why don't you put your 250m-300m to work either in accelerating your FOB work or in buying back shares ?
if you model the earnings of this company in 2 years to be very conservatively lovenox(with TL - 0m-pays expenses) and copaxone(120m) (excluding hidden goldmine of FOB characterization technology), your earnings would be approx >$2 per share..based on current price that is p/e of 8.5 or in other words a rate of return of 11.7%.
why then would you settle for keeping cash in bank at 1% return when you conservatively have potential of earning 11.7% return if you buy back shares ??